Skip to main content

Breast Cancer

New campuswide project will develop rapid manufacturing of tumor models

Researchers at the University of Illinois Urbana-Champaign will develop a radically new platform to manufacture tumor models and expand their availability for medical research and personalized medicine, thanks to a $21 million grant from the Advanced Research Projects...

A new approach to fighting breast cancer: Researchers identify compound that may help the immune system slow or stop tumor growth

For typical illnesses, the body’s immune system is a robust, pathogen-killing machine. It provides a general defense against harmful germs while also adapting and producing antibodies that target specific bacteria or viruses. After fighting off an infection like the flu, the body produces...

Overcoming drug resistance in breast cancer treatment

An interdisciplinary team of researchers from the University of Illinois has discovered a potential new treatment option for drug-resistant breast cancer. Their findings, published in Breast Cancer Research and Treatment,...

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75 percent of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these...

Team identifies key driver of cancer cell death pathway that activates immune cells

Scientists have identified a protein that plays a pivotal role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers.

Novel Compound May Block Certain Forms of Aggressive Cancer

University of Illinois scientists Benita Katzenellenbogen, Swanlund Professor of Molecular & Integrative Physiology, and John Katzenellenbogen, Swanlund Professor of Chemistry, have developed a new compound with efficacy in suppressing tumor initiation, progression, and metastasis of several...

Members of MCB labs earn newly-established fellowships focused on cancer research

The Beckman Institute has announced its 2023 class of six postdoctoral fellows. Fellows are selected in accordance with the core values of the institute: excellence, collaboration, integrity, transdisciplinarity, exploration, and diversity.

Experts boost activity of potential therapeutic target in triple-negative breast cancer

CHAMPAIGN, Ill. — Less than 20% of diagnosed breast cancers are designated “triple-negative,” meaning that the affected tissues lack three types of receptors often found in other breast cancer types, but TNBCs are often aggressive with ...

New therapeutic target identified for triple-negative breast cancer

Breast cancer is categorized into three major subtypes: hormone receptor-positive, HER2-positive, and triple-negative. Although there are targeted therapeutic approaches for the first two, there are limited options for triple negative-breast cancer patients. In a new study, researchers have...

Meet MCB: Molecular & Integrative Physiology PhD student Hashni Epa Vidana Gamage​

Hashni Epa Vidana Gamage​ is a PhD student in the School of Molecular and Cellular Biology at the University of Illinois Urbana-Champaign. In our latest "Meet MCB" video, Hashni shares what it means to her to be a part of a lab researching ways to improve breast cancer treatment.